Summit Trail Advisors LLC Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Summit Trail Advisors LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,533 shares of the medical equipment provider’s stock after acquiring an additional 1,095 shares during the quarter. Summit Trail Advisors LLC’s holdings in Zimmer Biomet were worth $480,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. BLB&B Advisors LLC lifted its position in shares of Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after purchasing an additional 100 shares during the last quarter. CKW Financial Group raised its stake in Zimmer Biomet by 11.7% in the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after buying an additional 100 shares in the last quarter. FWG Holdings LLC lifted its holdings in Zimmer Biomet by 2.9% during the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock worth $372,000 after buying an additional 101 shares during the last quarter. Romano Brothers AND Company boosted its position in shares of Zimmer Biomet by 1.1% during the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock worth $1,000,000 after acquiring an additional 102 shares in the last quarter. Finally, Financial Advocates Investment Management increased its holdings in shares of Zimmer Biomet by 3.5% in the 3rd quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after acquiring an additional 103 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.3 %

ZBH opened at $99.13 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.70. Zimmer Biomet Holdings, Inc. has a 12 month low of $98.94 and a 12 month high of $133.90. The stock has a market capitalization of $19.73 billion, a P/E ratio of 22.28, a P/E/G ratio of 1.83 and a beta of 1.02. The business has a 50 day simple moving average of $107.14 and a 200-day simple moving average of $107.99.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the company earned $2.20 earnings per share. On average, equities analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a yield of 0.97%. Zimmer Biomet’s payout ratio is currently 21.57%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on ZBH shares. Oppenheimer decreased their target price on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research note on Tuesday, October 15th. Wells Fargo & Company boosted their price objective on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JMP Securities reissued a “market outperform” rating and issued a $140.00 price target on shares of Zimmer Biomet in a research report on Friday, February 7th. Finally, JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $124.15.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.